Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20672040 | 0.88 | HTR6 (0.42) | PPARDHTR6BCHE | |
| SCHEMBL18617533 | 0.87 | PPARD (0.47) | S1PR1S1PR3PPARDNQO2MTNR1A | |
| SCHEMBL18618135 | 0.84 | PPARD (0.48) | S1PR1S1PR3PPARDHTR6NQO2 | |
| SCHEMBL18616751 | 0.75 | S1PR1 (0.49) | S1PR1S1PR3PPARDNQO2MTNR1A | |
| SCHEMBL18617329 | 0.74 | PPARD (0.44) | PPARDHTR6 | |
| SCHEMBL10224056 | 0.74 | GGPS1 (0.46) | BCHE | |
| SCHEMBL13865091 | 0.72 | ROCK1 (0.49) | — | |
| SCHEMBL12866793 | 0.72 | GGPS1 (0.50) | — | |
| SCHEMBL18616585 | 0.72 | PPARD (0.44) | PPARDHTR6 | |
| SCHEMBL13865089 | 0.71 | ROCK1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | S1PR1 2253/4885S1PR3 2123/4885PPARD 575/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | S1PR1 2253/4885S1PR3 2123/4885PPARD 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.